Harnessing TAGAP to improve immunotherapy for lung squamous carcinoma treatment by targeting c-Rel in CD4+ T cells

Cancer Immunology Immunotherapy, Год журнала: 2025, Номер 74(4)

Опубликована: Фев. 25, 2025

Abstract Revealing the immunosenescence, particularly in CD4+ T cell function lung squamous carcinoma (LUSC) assists devising individual treatment strategies. This study identifies differentially expressed genes (DEGs) between ROS1 mutated ( MUT ) and wild-type WT LUSC samples from TCGA database. Using WGCNA, immune-related DEGs (IRGs) were screened. Prognostic signatures derived IRGs used to compare immune infiltration, chemotherapy sensitivity, immune-phenotyping score (IPS) high- low-risk subgroups. Hub gene abundance different clusters was analyzed via Sc-seq. TAGAP overexpression or silencing employed assess its impact on cytokines production differentiation of cells, downstream c-Rel expression, tumor progression. High-risk subgroups exhibited decreased infiltration natural killer, follicular helper T, CD8+ but increased plasma, memory resting macrophage M2 cells. These more sensitive Sunitinib CTLA4 blockade. expression significantly reduced LUSC. Overexpressing enhanced cells produce cytokines, promoted into Th1/Th17 inhibited Treg conversion, suppressed phenotype vitro. also growth boosted vivo. TAGAP’s effects partly reversed by overexpression, highlighting TAGAP's role rejuvenating exerting anticancer inhibiting c-Rel. elucidates novel therapeutic potential targeting modulate activity immunotherapy for

Язык: Английский

Immunosenescence and immunotherapy in elderly patients with hepatocellular carcinoma

Seminars in Cancer Biology, Год журнала: 2025, Номер 111, С. 60 - 75

Опубликована: Фев. 26, 2025

Язык: Английский